Kenalog and Glucosamine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Kenalog (triamcinolone acetonide) and Glucosamine (glucosamine). Common drug interactions include infected dermal cyst among females and rash among males.

The phase IV clinical study analyzes what interactions people have when they take Kenalog and Glucosamine. It is created by eHealthMe based on reports of 32 people who take the same drugs from the FDA, and is updated regularly.

What is Kenalog?

Kenalog has active ingredients of triamcinolone acetonide. It is often used in pain. eHealthMe is studying from 10,692 Kenalog users. Check the latest studies of Kenalog.

What is Glucosamine?

Glucosamine has active ingredients of glucosamine. It is often used in joint pain. eHealthMe is studying from 15,547 Glucosamine users. Check the latest studies of Glucosamine.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 02, 2026

32 people who take Kenalog and Glucosamine together, and have interactions are studied.

Kenalog and Glucosamine drug interactions.

What are the common drug interactions of Kenalog and Glucosamine, by gender? *:

female:

  1. Infected dermal cyst
  2. Insomnia (sleeplessness)
  3. Lactic acidosis (low ph in body tissues)
  4. Meniere's disease (a disorder of the inner ear that can affect hearing and balance to a varying degree)
  5. Mobility decreased (ability to move is reduced)
  6. Nodule (a growth of abnormal tissue)
  7. Oropharyngeal pain
  8. Overweight
  9. Pain in extremity
  10. Paraesthesia oral (sensation of tingling, tickling, prickling, pricking, or burning of a person's oral with no apparent long-term physical effect)

male:

  1. Rash
  2. Diarrhoea
  3. Pruritus (severe itching of the skin)
  4. Swelling face
  5. Swollen tongue (swelling of tongue)
  6. Visual impairment
  7. White blood cell count decreased
  8. Fatigue (feeling of tiredness)
  9. Gait disturbance
  10. Dysphagia (a condition in which swallowing is difficult or painful)

What are the common drug interactions of Kenalog and Glucosamine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Blood glucose increased
  2. Blood potassium decreased
  3. Blood thyroid stimulating hormone increased
  4. Cerebral disorder (brain disease)
  5. Depression suicidal (suicide depressive disorder)
  6. Mobility decreased (ability to move is reduced)
  7. Tooth avulsion (complete displacement of a tooth from its socket)
  8. Insomnia (sleeplessness)
  9. Pain in extremity
  10. Sinusitis (inflammation of sinus)

60+:

  1. Fatigue (feeling of tiredness)
  2. Abdominal discomfort
  3. Petechiae (a small red or purple spot caused by bleeding into the skin)
  4. Ulcer haemorrhage (bleeding ulcer)
  5. Anaemia (lack of blood)
  6. Chills (felling of cold)
  7. Diarrhoea
  8. Dyspnoea (difficult or laboured respiration)
  9. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  10. Heart rate increased

What are the existing conditions these people have? *

  1. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 15.62%
  2. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 4 people, 12.50%
  3. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 4 people, 12.50%
  4. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 12.50%
  5. Lymphocytic Leukaemia (a type of cancer in which the bone marrow makes too many lymphocytes): 4 people, 12.50%
  6. Neuropathy Peripheral (surface nerve damage): 4 people, 12.50%
  7. Gait Disturbance: 4 people, 12.50%
  8. High Blood Pressure: 3 people, 9.38%
  9. Fatigue (feeling of tiredness): 3 people, 9.38%
  10. Hyperlipidaemia (presence of excess lipids in the blood): 3 people, 9.38%

* Approximation only. Some reports may have incomplete information.

Do you take Kenalog and Glucosamine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Kenalog and Glucosamine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Kenalog:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Glucosamine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Kenalog and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Glucosamine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on triamcinolone acetonide and glucosamine (the active ingredients of Kenalog and Glucosamine, respectively), and Kenalog and Glucosamine (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: